Cargando…

Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy

Background: Current treatment guidelines for arrhythmogenic right ventricular cardiomyopathy (ARVC) mainly emphasize on prevention of ventricular arrhythmic events. Despite the progressive nature of ARVC, therapeutic options focusing on decelerating disease progression are scarce. Methods and Result...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tu, Bin, Wu, Lingmin, Zheng, Lihui, Liu, Shangyu, Sheng, Lishui, Liu, Limin, Zhu, Zhenghui, Yao, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632763/ https://www.ncbi.nlm.nih.gov/pubmed/34869685 http://dx.doi.org/10.3389/fcvm.2021.769138

Ejemplares similares

Arrhythmic risk stratification in arrhythmogenic right ventricular cardiomyopathy
por: Gasperetti, Alessio, et al.
Publicado: (2023)

Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator( )
por: Jordà, Paloma, et al.
Publicado: (2022)

Plasma testosterone and arrhythmic events in male patients with arrhythmogenic right ventricular cardiomyopathy
por: Ren, Jie, et al.
Publicado: (2020)

Clinical Identification and Characteristic Analysis of Giant Cell Myocarditis in 12 Cases
por: Liu, Shangyu, et al.
Publicado: (2021)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients
por: Huang, Linna, et al.
Publicado: (2021)

Impact of Exercise Restriction on Arrhythmic Risk Among Patients With Arrhythmogenic Right Ventricular Cardiomyopathy
por: Wang, Weijia, et al.
Publicado: (2018)

Layer-Specific Global Longitudinal Strain Predicts Arrhythmic Risk in Arrhythmogenic Cardiomyopathy
por: Segura-Rodríguez, Diego, et al.
Publicado: (2021)

Efficacy and Safety of Angiotensin Receptor Blockers in a Pre-Clinical Model of Arrhythmogenic Cardiomyopathy
por: Landim-Vieira, Maicon, et al.
Publicado: (2022)

Acute episode of an arrhythmogenic right ventricular cardiomyopathy with vast necroses exclusively in right ventricular myocardium
por: Gattenlöhner, Stefan, et al.
Publicado: (2009)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
por: Liu, Tao, et al.
Publicado: (2023)

Right Ventricular Cardiomyopathy Meeting the Arrhythmogenic Right Ventricular Dysplasia Revised Criteria? Don't Forget Sarcoidosis!
por: Vasaturo, Sabina, et al.
Publicado: (2015)

Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy
por: Matsumura, Yoshihisa, et al.
Publicado: (2015)

The appropriate dose of angiotensin‐converting‐enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?
por: Ishida, Junichi, et al.
Publicado: (2015)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Arrhythmogenic right ventricular cardiomyopathy
por: Cho, Yongkeun
Publicado: (2018)

Arrhythmogenic Right Ventricular Cardiomyopathy
por: Dolkar, Tsering, et al.
Publicado: (2022)

Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?
por: Brooks, John M., et al.
Publicado: (2018)

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
por: Simko, Fedor, et al.
Publicado: (2021)

Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy
por: Liu, Limin, et al.
Publicado: (2020)

Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias
por: Schupp, Tobias, et al.
Publicado: (2022)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
por: Indik, Julia H, et al.
Publicado: (2003)

Arrhythmogenic right ventricular cardiomyopathy/dysplasia
por: Thiene, Gaetano, et al.
Publicado: (2007)

Focus on arrhythmogenic right ventricular cardiomyopathy
por: Sinagra, Gianfranco, et al.
Publicado: (2020)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Effect of rs4646994 polymorphism of angiotensin-converting enzyme on the risk of nonischemic cardiomyopathy
por: Shen, Jinsheng, et al.
Publicado: (2021)

The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin‐converting enzyme inhibitor in dilated cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2022)

Dilated right heart in a young lady with syncope: atrial septal defect masquerading as arrhythmogenic right ventricular cardiomyopathy
por: Shenoy, Sundeep, et al.
Publicado: (2021)

Prolonged Postoperative Vasoplegia in Pediatric Patients on Chronic Angiotensin II Blocker Treatment
por: Pandya, Nischal R., et al.
Publicado: (2018)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Dominant Myocardial Fibrosis and Complex Immune Microenvironment Jointly Shape the Pathogenesis of Arrhythmogenic Right Ventricular Cardiomyopathy
por: Lu, Wenzhao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9747rshemqjcmf969skueuuboh